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S U M M A R Y
Objectives: The aim of this study was to determine the epidemiological and clinical characteristics of
children with respiratory syncytial virus (RSV) treated at a public referral children’s hospital in Mexico.
Methods: We reviewed RSV infection in patients aged 0–18 years who were treated at Hospital Infantil
from January 2004 to December 2008.
Results: During the 5 years, 2797 samples were tested for respiratory viruses; 356 samples were positive
for any virus, including 266 (74.7%) positive for RSV. Complete clinical information was available for 205
RSV patients. The mean age was 22 months, and 33.7% of the infections were nosocomially acquired.
Hospitalization occurred in 187 children. Of 14 deaths, nine were directly attributed to RSV infection.
During the study, RSV infections were seen throughout the year, predominating in the colder months. Of
the 205 patients, 79.0% (162/205) had an underlying disease. Congenital heart disease was found in
30.2% (49/162), including three children (33.3%) who died of RSV. Thirty-three patients (16.1%) with RSV
required mechanical ventilation. None of the children with RSV received palivizumab or ribavirin.
Conclusions: RSV caused high hospitalization rates and admission to intensive care units, especially
among those with underlying illnesses and young infants. The data presented here will be useful for
strategies to improve outcomes in children at risk of complications.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Respiratory syncytial virus (RSV) is an important cause of viral
lower respiratory tract infections in infants and children world-
wide,1,2 and it is a signiﬁcant pathogen in immune-compromised
hosts and those with underlying cardiopulmonary diseases.3–5
Globally, the RSV burden is estimated at 64 million cases and
160 000 deaths annually;6 for those younger than 1 year old, the
estimated RSV mortality rate was shown to be more than nine
times that of inﬂuenza.7 A recent prospective study of Kenyan
infants and children hospitalized with severe pneumonia showed
that RSV was the predominant pathogen isolated,8 and other
studies have shown similar ﬁndings.9,10
RSV is transmitted by contact with infectious droplets. An
incidence of nosocomial RSV infection of 6% (90 of 1568
documented RSV infections) was reported in a prospective
multicenter surveillance study done in Germany covering six* Corresponding author. Tel.: +1 901 595 4194; fax: +1 901 595 2099.
E-mail address: miguela.caniza@stjude.org (M.A. Caniza).
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http://dx.doi.org/10.1016/j.ijid.2012.03.001consecutive seasons from 1999 to 2005.11 Some investigators
suggest that the true incidence of nosocomial RSV may be
underestimated.12 In a recent study in a general hospital in
Mexico, investigators found that RSV was responsible for 26% of
conﬁrmed respiratory infections among those tested for RSV in
children younger than 5 years old.13
To better understand the contribution of RSV infection to the
morbidity and mortality of very high risk children, we analyzed the
clinical characteristics and epidemiology of RSV in pediatric
patients aged 0–18 years and their outcomes at Hospital Infantil
de Me´xico Federico Go´mez (Hospital Infantil) during 2004–2008.
2. Materials and methods
2.1. Setting
Hospital Infantil is a public, multi-specialty, teaching and
referral hospital with 290 beds for children aged 0–18 years
located in Mexico City. Patients admitted to Hospital Infantil are
those with complex diseases who require highly specialized care
and come from Mexico City, the surrounding communities, andses. Published by Elsevier Ltd. All rights reserved.
Table 1
Viruses identiﬁed in respiratory infections at Hospital Infantil, 2004–2008
Virus Year Total
2004 2005 2006 2007 2008
RSV 49 57 23 89 48 266
Parainﬂuenza 3 2 1 4 18 4 29
Inﬂuenza A 1 3 0 21 0 25
Parainﬂuenza 2 2 1 0 3 7 13
Parainﬂuenza 1 7 0 1 0 3 11
Adenovirus 2 2 0 4 1 9
Inﬂuenza B 0 1 0 1 1 3
Total positive 63 65 28 136 64 356
Total negative 215 366 391 774 695 2441
RSV, respiratory syncytial virus.
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meters (7350 feet) above sea level, and the cooler months are from
November through February. Patients with RSV are allocated
single-bed rooms if available, or are placed in rooms with other
patients with RSV. Hospital Infantil is one of the three most
important teaching pediatric centers in Mexico City, however
other care centers for children who require hospitalization also
exist in the city. During the study years, the average annual
discharge was 6356 patients, and bed occupancy was 85.2%.
2.2. Study population and design
We conducted a retrospective, observational study that
included all consecutive patients aged 0–18 years at Hospital
Infantil with respiratory symptoms and a positive antigen test for
RSV using an indirect immunoﬂuorescence antibody assay (IFA)
during the study period of January 1, 2004 through December 31,
2008. By using the microbiology laboratory registry, we con-
structed a list of patients with respiratory infections for whom
respiratory virus testing was required. Patients who were positive
for RSV and for whom complete demographic data and medical
information were available were included in the study. Medical
information required included underlying disease, date of onset of
disease to determine whether community- or hospital-acquired,
length of hospital stay, wards in which they were hospitalized,
clinical presentation, laboratory information, development of
complications, illness severity, and deaths related to RSV infection.
Information was collected regarding initial hospital site of care
where respiratory samples were obtained and signs and symptoms
on presentation, such as cough, rhinorrhea, bronchospasm,
respiratory distress, apnea, cyanosis, and fever (38 8C). The
severity of the clinical status was determined on the basis of
whether admission to the intensive care unit was required and
whether mechanical ventilation was needed. The decision
regarding tracheal intubation was determined by the patients’
clinical status using the Silverman–Andersen score.14 RSV infec-
tion was considered nosocomial when the symptoms appeared on
inpatient day 6 or later and if patients were readmitted with RSV
less than 5 days after discharge and the ﬁrst admission was for a
non-RSV illness.15,16 The study was approved by the Institutional
Research Ethics Committee of Hospital Infantil.
2.3. Sample collection and laboratory processing
All children with symptoms of viral upper or lower respiratory
tract infection attending Hospital Infantil had nasal swabs taken
for the study of the respiratory virus as part of the standard of care.
Rayon-tipped, aluminum-shafted swabs (Copan Italia S.p.a.,
Brescia, Italy) were used to collect nasal secretion samples, and
bronchial aspirate was collected from those who were intubated.
To identify RSV antigen in the respiratory samples, an IFA was
performed (Light Diagnostics Respiratory Panel I Viral Screening
and Identiﬁcation IFA, Millipore (UK) Ltd) for the detection of
parainﬂuenza virus types 1, 2, and 3, adenovirus, inﬂuenza types A
and B, and RSV. Metapneumovirus and rhinovirus were not tested
for. The assay was conducted in accordance with the manufac-
turer’s instructions. The samples were obtained at the point of
patient care (i.e., the emergency department, intensive care units,
or other inpatient wards).
2.4. Statistical methods
Frequencies and comparisons of variables in the information
obtained were analyzed using SPSS version 16. Descriptive
statistics such as means and proportions were used to report
origin, month of diagnosis, age, hospitalization ward, lengthof hospitalization, underlying illnesses, and severity of RSV
infection.
3. Results
3.1. Study population
A total of 2797 respiratory secretion samples were collected
from the same number of patients, and these samples were studied
in the microbiology laboratory of Hospital Infantil. From 356
samples that were positive for any respiratory viral agent, RSV was
the most frequently isolated virus (266, 74.7%; Table 1). For our
study we selected 205 patients for whom complete clinical data
were available. We had no clinical information on 61 patients
(22.9%) with RSV infection, so they were excluded from further
study. Occasionally, children who do not receive routine care at
Hospital Infantil are tested in this hospital’s laboratories. These
children often do not have medical records at this hospital, and it is
likely that the children in the group that we excluded for lack of
clinical information were such children.
3.2. Demographic characteristics
The demographic and clinical characteristics of the 205 study
subjects are shown in Table 2. The mean age of the patients was 22
months (range 0.6–180 months), and the median and the mode
were 9 and 2 months, respectively. Eighty percent (164/205) of the
patients infected with RSV were aged 24 months (Figure 1), and
50% were aged between 4 months (ﬁrst quartile) and 21 months
(third quartile). There were 105 girls and 100 boys. Of the 205
patients, 187 (91.2%) required hospitalization. Most of the patients
(162/205, 79.0%) with RSV infections had an underlying disease,
such as congenital heart disease (CHD; 49/162, 30.2%) and
neoplastic diseases (28/162, 17.3%).
In most other reports, RSV has been seen in younger patients
(i.e., those younger than 6 months);2,17 the mean age in our study
was higher, but other measures of central tendencies (median and
mode) were lower than the mean because of the asymmetric age
distribution of our sample population (positively skewed). Thus,
more than 60% were older than 6 months, in whom hospitalization
was most likely due to underlying illnesses. Among patients with
RSV infection, 12.8% were born at less than 34 weeks of gestation,
11.7% were born between 34 and 37 weeks of gestation, and 75.5%
were full-term infants. Most of the patients (82.4%) originated from
Mexico City and surrounding areas and the rest (17.6%) were from
other regions of Mexico.
3.3. Epidemiology of RSV infections at Hospital Infantil
Most of the samples (112/205, 54.6%) were collected while the
patients were in the emergency room; the rest were collected from
Table 2
Demographics and clinical characteristics of 205 patients with RSV infections at
Hospital Infantil, 2004–2008
Demographics and characteristics Result, % (n)
Mean age in months 22 (range 0.6–180)
Females 51.2% (105)
Underlying diseasea 79.0% (162 patients
with 175 diseasesb)
Congenital heart disease 28% (49)
Neoplastic disease 16% (28)
Down syndrome 9.1% (16)
Bronchopulmonary dysplasia 5.7% (10)
Hepatopathy 5.7% (10)
Neurological diseases 5.7% (10)
Gastrointestinal disease 4.6% (8)
Congenital malformation – non-cardiac 4% (7)
Steroid use 4% (7)
HIV 3.4% (6)
Endocrine/metabolic 2.9% (5)
Infectious process – non-viral 2.9% (5)
Hematological – non-malignant 2.3% (4)
Pulmonary disease 2.3% (4)
Cystic ﬁbrosis 1.1% (2)
Renal disease 1.1% (2)
Otherc 1.1% (2)
Community-acquired RSV infection 66.3% (136)
Nosocomially-acquired RSV infectiond 33.7% (69)
Point of care when diagnostic sample taken
Emergency room 54.6% (112)
General ward 26.3% (54)
Surgery 7.3% (15)
Oncology 5.4% (11)
Intensive care unit 3.4% (7)
Neonatal intensive care unit 2.9% (6)
Diagnostic sample type
Nasal swab 83.9% (172)
Bronchial aspirate 16.1% (33)
Respiratory symptoms
Cough 80% (164)
Fever 55.6% (114)
Respiratory distress 47.8% (98)
Rhinorrhea 43.9% (90)
Apnea 3.9% (8)
<3 months 100% (8)
Diagnosis
Pneumonia 65.3% (134)
Bronchiolitis 13.2% (27)
Pharyngitis 12.7% (26)
Other 8.8% (18)
Antibiotics upon admission 67.3% (138)
a Some individuals had more than one underlying disease; total of 175 diseases.
b Denominator for underlying diseases subgroup = 175 diseases.
c Other diseases included a case of cervical lymphangioma and a case of
craniosynostosis.
d A nosocomial RSV infection in our study was deﬁned by onset of symptoms on
or after day 6 of hospitalization.
Figure 1. Age distribution of conﬁrmed RSV infection cases at Hospital Infantil,
2004–2008 (n = 205).
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205, 7.3%), oncology (11/205, 5.4%), intensive care unit (7/205,
3.4%), and neonatal intensive care unit (6/205, 2.9%). Most cases
occurred in the fall (147/266, 55.3%), with 31.6% (84/266) in
winter, 6.0% (16/266) in spring, and 7.1% (19/266) in summer.
During the 5 years of the study, RSV infections were less common
during the warmer months of the year (March to June), and peaked
during the cooler months (August to March), changing year to year
(Figure 2). Approximately a third (69/205, 33.7%) of the RSV
infections were acquired in the hospital, and the rest were acquired
in the community (136/205, 66.3%). The duration of hospitalization
of patients with community-acquired infection ranged from 1 to
70 days (median 7 days). Of those inpatients, 49.3% (67/136) stayed
less than 7 days, 27.9% (38/136) stayed 7–14 days, and 22.8% (31/
136) stayed more than 14 days.3.4. Clinical presentation and severity
At presentation, the patients had cough (164/205, 80%), fever
(114/205, 55.6%), respiratory distress (98/205, 47.8%), and rhinor-
rhea (90/205, 43.9%). The most frequent ﬁndings by lung
auscultation were crackles (98/205, 47.8%), rattles (117/205,
57.1%), and wheezing (55/205, 26.8%). Eight patients (3.9%) had
apnea. The most frequent clinical diagnoses were pneumonia (134/
205, 65.3%), bronchiolitis (27/205, 13.2%), and pharyngitis (26/205,
12.7%). Other less frequent diagnoses were atypical pneumonia (8/
205, 3.9%), rhinitis (5/205, 2.4%), and otitis (3/205, 1.5%). Of the 111
patients with chest radiographs, 25.2% (28/111) had interstitial
inﬁltrates, 23.4% (26/111) had perihilar inﬁltrates, and 18.0% (20/
111) had lung overdistention. Other radiology ﬁndings were
bilateral inﬁltrates, consolidation, inﬁltrates in both bases, and
atelectasis. Most of the patients (138/205, 67.3%) received
antibiotics upon admission to the hospital. The most frequently
used antibiotics for suspected bacterial pneumonia were ampicil-
lin (22.4%), cefuroxime (20.2%), and cefotaxime plus dicloxacillin
(13.0%). Other antibiotics used were clarithromycin, cefepime plus
amikacin, and amoxicillin/clavulanic acid.
In terms of the illness severity, 33/205 (16.1%) required
mechanical ventilation and 14 of these children (42.4%) died.
Nine deaths occurred at <30 days after testing positive for RSV and
were possibly related to the RSV infection, giving a global mortality
rate of 4.4% (9/205); the ﬁve other deaths occurred 30 days after
the initial diagnosis of RSV and these deaths were not directly
attributed to RSV. The mean age of the patients who died was 12
months. Five of the patients who died had a nosocomially-acquired
RSV infection (Table 3). No prophylaxis with palivizumab or
treatment with ribavirin was used in any of the patients in this
study.
4. Discussion
RSV was the most frequent viral pathogen found in respiratory
samples tested using IFA in Hospital Infantil during the 5-year
study period from 2004 to 2008, accounting for 74.7% of all the
respiratory viruses isolated from patients with respiratory tract
infections. Most of the children with RSV required hospitalization,
and more than three quarters were younger than 2 years old. In
contrast to other published RSV epidemiologic studies,2,13,18 the
patients we describe here were at high risk for RSV complications
and were not receiving RSV prophylaxis. As a result, many of them
were hospitalized. The most frequent underlying diseases among
these hospitalized children were CHD, malignancies, and bronch-
opulmonary disease (BPD). Most of the patients had respiratory
symptoms; some were severe and the patients required admission
to the intensive care unit and assisted mechanical ventilation.
Figure 2. Seasonal and monthly distribution of subjects tested (n = 2797) for respiratory viruses and RSV detection (n = 266) from 2004 to 2008 in Hospital Infantil.
Table 3
Deaths in RSV-infected children at Hospital Infantil, 2004–2008
Patienta Age (months) Sex Ward Date of diagnosis Source of RSV Underlying diagnosis Infectious syndrome ICU admission
1 168 M ICU 01/08/2004 Community Down syndrome Pneumonia Yes
2 2 M ICU 03/01/2004 Nosocomial BPD Pneumonia Yes
3 4 F IDU 12/15/2004 Nosocomial BPD Pneumonia No
4 5 F ER 02/01/2006 Community CHD Pneumonia No
5 12 M ICU 10/05/2006 Community Previously healthy Pneumonia Yes
6 26 F ER 03/15/2007 Community CHD Pneumonia No
7 180 F ER 09/17/2007 Community SLE and high dose steroid use Pneumonia No
8 7 F ICU 10/17/2007 Community CHD Pneumonia Yes
9 21 F ER 10/21/2008 Community West syndrome Pneumonia No
10 5 M ER 11/27/2008 Community Neuropathy Pneumonia No
11 3 F ER 08/29/2007 Community CHD Pneumonia No
12 5 F ICU 02/23/2004 Nosocomial CHD Pneumonia Yes
13 4 M ER 03/09/2004 Nosocomial Previously healthy Pneumonia No
14 4 M ER 11/15/2007 Nosocomial Down syndrome Pneumonia No
RSV, respiratory syncytial virus; ICU, intensive care unit; ER, emergency room; IDU, infectious disease unit; M, male; F, female; BPD, bronchopulmonary dysplasia; CHD,
congenital heart disease; SLE, systemic lupus erythematosus.
a Patients 1–9 died within 30 days of the diagnosis of RSV infection; patients 10–14 died 30 days or more after the diagnosis of RSV infection.
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patients who died.
It is well established that most infants are infected with RSV by
2 years of age,19 and that the majority of these infections are
symptomatic.20 Lower respiratory tract infections occur in up to
one third of symptomatic infections necessitating hospitaliza-
tion.20 The lower the age of these children, the higher the need for
hospitalization.21 Mortality from RSV infection is low in healthy
children, but this is increased in children with cardiac disease,
chronic respiratory disease, or immune deﬁciencies.22 At Hospital
Infantil, 80% (n = 164) of the participants were younger than 2
years of age. In this group, almost three quarters (n = 121, 73.8%)
had an underlying disease. The mortality due to RSV was higher in
this group of children with underlying diseases (n = 8, 6.6%) than in
those without underlying diseases (n = 1, 2.3%).
In a study conducted by Garcı´a et al.18 in Texas among children
less than 2 years of age with bronchiolitis, it was found that 2840
children had RSV and that 770 (27.1%) of those children had risk
factors such as prematurity, cardiopulmonary pathologies, con-
genital syndromes, immunodeﬁciencies, and neuromuscular dis-
orders. Three children with RSV died (0.1%), and two of them
(0.26%) had risk factors (one with congenital heart disease and the
other had Moebious syndrome). The authors indicated that lower
RSV infections in children with risk factors were most likely due to
anti-RSV prophylaxis; however, the author pointed out that better
prevention strategies are necessary.
Another study conducted by Noyola et al.13 studied respiratory
infections among children less than 3 years of age in a publicgeneral hospital in Mexico during a period of 24 months. RSV was
detected in 153 of 616 subjects with respiratory infections. From
this group, 120 (78.4%) infants with RSV infections were previously
healthy and 33 (21.6%) had one or more underlying disorders.
There were no deaths during the study period. Hospital Infantil is
one of the few public and tertiary pediatric centers in Mexico, and
children at high risk of RSV morbidity and mortality concentrate at
this institution. Infected children often need frequent and/or
prolonged hospitalization and access to intensive care units and
mechanical ventilation, which increases the morbidity from RSV.
In this hospital, as in most public hospitals in Mexico, high-risk
children who qualify for seasonal RSV prophylaxis do not currently
receive palivizumab, and if infected with RSV they do not receive
speciﬁc antivirals for RSV. Some published studies have reported
children with RSV at risk for complications separately from healthy
children, 3,4,11,18 and in others, the populations of healthy and at-
risk children have been different to our study sample;8,12,13
therefore, our results are different due to the characteristics of the
patients attending Hospital Infantil.
One third of the RSV cases were acquired in the hospital.
Nosocomial RSV infection in immunocompromised patients and
those with CHD places them at high risk for severe, often fatal, RSV
pneumonia.3,7 In addition, the risk of death is higher among
children who acquire an RSV infection nosocomially than among
those who acquire RSV in the community.4,5 When implementing
targeted interventions based on education of health care providers
and adherence to infection prevention and control measures, the
transmission rates decrease substantially.23,24 RSV can survive on
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and stethoscopes after 30 min.24 Factors associated with nosoco-
mial acquisition of RSV infection are young age, underlying or
chronic disease, long hospitalization, crowding, suboptimal staff-
to-patient ratio, and lack of good infection prevention practices
such as isolation precautions, good hand hygiene, and visitation
policies.6,23,24We observed that most of these factors were present
at Hospital Infantil during the study period. The most important
measure for preventing infections is avoiding disease transmission
and acquisition in the ﬁrst place.25 Infection prevention strategies
are recommended to curb the transmission of respiratory viruses,
including RSV. To lessen the rates of transmission during
hospitalization, an institution-wide program must be established,
preferably as part of an infection prevention and control
program.24,26,27 Guidelines recommend rapid patient diagnosis,
compliance with acceptable hand hygiene techniques, and
cohorting of patients and staff.16,26 Emphasis on health care
provider compliance with optimum prevention practices during
epidemics must be the goal to decrease rates of nosocomial
infection.28
One ﬁfth of the hospitalized children with RSV at Hospital
Infantil acquired the infection in the community and required
mechanical ventilation. The mortality was higher in those with
underlying diseases. During the 5-year study period, none of the
infants and children who qualiﬁed for prophylaxis received
palivizumab. Reasons for not using this pharmacologic interven-
tion were its cost and other competing needs at Hospital Infantil,
which is a resource-limited public hospital. In children with risk
factors for severe RSV, palivizumab, a humanized mouse antibody,
is recommended during the RSV season.16,29 Like other immune-
mediated factors, palivizumab functions by targeting the highly
conserved RSV F glycoprotein, inhibiting viral entry into host
cells.30 Factors that lead to effective results in the use of
palivizumab are safety and tolerability, ease of administration,
and lack of interference with normal vaccinations. With the
exception of a few reports29,31,32 in which therapy with
palivizumab was successful in treatment, the primary indication
in the use of this monoclonal antibody is for RSV prevention.30,33
Vaccination provides the best way to elicit a durable and effective
immune response to an infection. Unfortunately, to date, no
effective RSV vaccine has been developed. Until a good vaccine is
available, measures to prevent infection during epidemics include
the use of palivizumab and optimum infection prevention and
control practices.34
At Hospital Infantil, patients with RSV received hydration and
nutritional and respiratory supportive care, including the use of
bronchodilators and steroids, following current and ofﬁcial
guidelines, such as those of the American Academy of Pediatrics.16
Treatment of RSV bronchiolitis, in addition to supportive care,
must be individualized and provided early in the illness;35 use of
bronchodilators and steroids is common during the care of RSV
bronchiolitis. According to some experts and based on the results
of a meta-analysis of published studies, bronchodilators such as
racemic epinephrine, salbutamol, and ipratropium bromide,
despite transient relief of respiratory distress, have no beneﬁcial
effects on acute RSV bronchiolitis.36,37 More studies are needed for
conclusive recommendations. Likewise, steroid use early in the
course of the infection has demonstrated beneﬁts,38,39 but support
for conclusive recommendations are also needed. Systematic
improvement in supportive measures, such as respiratory support
therapy, hydration, and nutrition, can produce substantial results.
Cost-effective actions such as these are amenable to hospitals like
Hospital Infantil. These actions may positively affect survival
among very young children and those with underlying diseases.
Hospital Infantil is one of three main hospitals in Mexico City
for referral of highly complex pediatric disease cases, includingthose children with CHD, other congenital malformations,
prematurity, and immunodeﬁciency. Therefore, it was not
surprising to ﬁnd that the most frequent underlying diseases
among children hospitalized for RSV infection at Hospital Infantil
were CHD, malignancies, and BPD. Children with those pathologies
have a more severe RSV course and often need hospital care for the
complications of the underlying pathology and the RSV infec-
tion.3,7,22 Also, these patients often require prolonged hospitaliza-
tion, thus increasing the chance of acquiring infections
nosocomially, such as RSV infections during RSV epidemics.15
Our study provides a better understanding of the yearly RSV
epidemics and their contribution to the burden of respiratory
infections among our patients at Hospital Infantil. Data on the
seasonality of RSV and institutional care and prevention guidelines
are particularly useful to health care providers for the management
of patients at high risk of morbidity and mortality and to
administrators for planning and implementing cost-effective
policies to satisfy the needs of such patients, especially during
epidemics. These guidelines work better when adapted to the
available resources and unique needs at each site; implementation
and compliance with these guidelines during the RSV season has
been shown to make a difference in outcomes.40 Our ﬁndings,
which were shared with the leaders of Hospital Infantil, initiated
improvements in planning and implementing infection prevention
and control strategies, especially for high-risk patients. As a direct
result of our study, we are currently working on best care and
prevention practice guidelines for respiratory infections at
Hospital Infantil.
Limitations of our study include its retrospective nature, the
fact that we obtained a relatively low number of positive RSV
results, and that complete information was not available for almost
25% of patients with RSV infections. Weaknesses of retrospective
studies are that they rely on existing medical records that were
collected for reasons other than research, and when speciﬁc
information is absent, this is difﬁcult to resolve. Also, it is difﬁcult
to control biases and confounders in this type of study. However,
retrospective studies are inexpensive, use existing records, and
more importantly can generate hypotheses that can be tested
prospectively.41 Our study had a relatively small number of
positive respiratory virus results, including RSV, and we speculate
on several possible reasons. First, we included the reports of all
respiratory samples regardless of when in the duration of illness
the sample was collected. The threshold for obtaining a respiratory
sample in our patients was low, because most of them had serious
risk factors for complications of RSV infection. In other studies8,13 a
case deﬁnition was used for the collection of respiratory samples.
Second, we used only one laboratory method (IFA) for testing viral
pathogens. The sensitivity of IFA is less than other methods such as
PCR and serology, which have been used in other studies.42,43 And
ﬁnally, obtaining more than one sample improves the success of
getting a positive result. Improving the stated limitations in the
study design, sample collection, and laboratory methods will
increase the success in ascertaining positive laboratory results.
Reviewing the work ﬂow at Hospital Infantil, it was estimated that
most of the patients we lacked information for were not admitted
to the hospital, and we concluded that their clinical course must
have been mild. Even when including patients with incomplete
information into our calculations, the hospitalization rate was still
high (187 of 266 children with positive RSV tests). The participants
discussed in this report consist of patients who had a conﬁrmed
RSV infection and most of them were admitted to Hospital Infantil.
As such, almost 80% of the patients had an underlying disease and
therefore a much higher risk of complications. Also, because
Hospital Infantil is a referral center for patients with complex
diseases, the epidemiology and outcomes may be different in a
hospital treating children with less complex diseases.44 However,
J.P. Rodrı´guez-Auad et al. / International Journal of Infectious Diseases 16 (2012) e508–e513 e513we think that since the conditions at Hospital Infantil may mirror
other hospitals of similar socioeconomic background and referral
patterns, the information presented here will be useful in guiding
the formulation of local policies for the treatment and prevention
of RSV and, most importantly, for allocating institutional resources,
including personnel, for best care and prevention of RSV during
epidemic seasons.
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